{"id":"gensci094","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Carpal tunnel syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GenSci094 functions as a growth hormone receptor agonist, binding to and activating growth hormone receptors to stimulate anabolic effects including increased protein synthesis, lipolysis, and linear growth. The drug is developed as a therapeutic option for growth hormone deficiency and related growth disorders.","oneSentence":"GenSci094 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:59.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency"},{"name":"Growth disorders in pediatric patients"}]},"trialDetails":[{"nctId":"NCT06321107","phase":"","title":"Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-03-01","conditions":"Infertility","enrollment":158},{"nctId":"NCT06091436","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-03-24","conditions":"Infertility","enrollment":176},{"nctId":"NCT06095206","phase":"PHASE1","title":"The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site","status":"COMPLETED","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2023-09-19","conditions":"Infertility","enrollment":48},{"nctId":"NCT06561594","phase":"PHASE3","title":"To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-09-20","conditions":"Idiopathic Hypogonadotropic Hypogonadism","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GenSci094","genericName":"GenSci094","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GenSci094 is a recombinant human follicle-stimulating hormone-CTP fusion protein injection being studied in a clinical trial for the treatment of Idiopathic Hypogonadotropic Hypogonadism and Infertility. The trial is a multicenter, randomized, double-blind study that also includes a placebo group, and is being conducted by Changchun GeneScience Pharmaceutical Co., Ltd.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}